2024 annual financial data
China SXT Pharmaceuticals 2024 Operating margin
China SXT Pharmaceuticals 2024 operating margin with verified reported values.
Direct answer
Operating margin was -130.42%.
Operating income was -2,515,217 USD and net income was -3,098,532 USD.
Operating cash flow was -1,928,053 USD.
Get free China SXT Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,928,497 USD
- Operating income
- -2,515,217 USD
- Net income
- -3,098,532 USD
- Operating cash flow
- -1,928,053 USD